Outlook Therapeutics Q2 Net Loss $4.5M; Awaits FDA ONS-5010 Decision
Outlook Therapeutics, Inc. reported a significant reduction in its GAAP net loss for the second fiscal quarter ended March 31, 2026, to $4.5 million, or $0.05 per share, compared to $46.4 million, or $1.50 per share, in the prior year. The company completed its formal dispute resolution meeting with the FDA regarding ONS-5010, with a decision expected in May 2026. Concurrently, Outlook Therapeutics continued its European commercial expansion of LYTENAVA, securing a distribution agreement for Switzerland and planning launches in the Netherlands and Ireland later in 2026, despite a 10% sequential dip in European unit sales. The company also strengthened its financial position through recent public and registered direct offerings, raising a total of $8.2 million in net proceeds.
Key Highlights
- Q2 FY2026 net loss attributable to common stockholders significantly reduced to $4.5M from $46.4M YoY.
- Q2 FY2026 net loss per share was $0.05, down from $1.50 in the prior year.
- Adjusted net loss for Q2 FY2026 increased to $14.1M from $12.4M YoY.
- Formal dispute resolution meeting with FDA for ONS-5010 completed; decision expected in May 2026.
- Signed Commercial Distribution Agreement with Mediconsult AG for LYTENAVA in Switzerland, targeting 2027 launch.
- Plans to expand LYTENAVA commercial rollout into Netherlands and Ireland later in 2026.
- Cash and cash equivalents were $7.7M as of March 31, 2026.
- Raised $4.0M net from a March 2026 public offering and $4.2M net from an April 2026 offering.
Price Impact
More from OTLK